148 related articles for article (PubMed ID: 37566399)
1. ANXA1 Promotes Tumor Immune Evasion by Binding PARP1 and Upregulating Stat3-Induced Expression of PD-L1 in Multiple Cancers.
Xiao D; Zeng T; Zhu W; Yu ZZ; Huang W; Yi H; Lu SS; Feng J; Feng XP; Wu D; Wen Q; Zhou JH; Yuan L; Zhuang W; Xiao ZQ
Cancer Immunol Res; 2023 Oct; 11(10):1367-1383. PubMed ID: 37566399
[TBL] [Abstract][Full Text] [Related]
2. ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers.
Yu ZZ; Liu YY; Zhu W; Xiao D; Huang W; Lu SS; Yi H; Zeng T; Feng XP; Yuan L; Qiu JY; Wu D; Wen Q; Zhou JH; Zhuang W; Xiao ZQ
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 37001908
[TBL] [Abstract][Full Text] [Related]
3. PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3.
Ding L; Chen X; Xu X; Qian Y; Liang G; Yao F; Yao Z; Wu H; Zhang J; He Q; Yang B
Cancer Immunol Res; 2019 Jan; 7(1):136-149. PubMed ID: 30401677
[TBL] [Abstract][Full Text] [Related]
4. Hepatoma cell-intrinsic TLR9 activation induces immune escape through PD-L1 upregulation in hepatocellular carcinoma.
Zhou B; Yan J; Guo L; Zhang B; Liu S; Yu M; Chen Z; Zhang K; Zhang W; Li X; Xu Y; Xiao Y; Zhou J; Fan J; Hung MC; Li H; Ye Q
Theranostics; 2020; 10(14):6530-6543. PubMed ID: 32483468
[TBL] [Abstract][Full Text] [Related]
5. TLR9 activation induces immunosuppression and tumorigenesis via PARP1/PD-L1 signaling pathway in oral squamous cell carcinoma.
Ma L; Qin N; Wan W; Song S; Hua S; Jiang C; Li N; Huang L; Gao X
Am J Physiol Cell Physiol; 2024 Feb; 326(2):C362-C381. PubMed ID: 38105756
[TBL] [Abstract][Full Text] [Related]
6. Alpha5 nicotinic acetylcholine receptor mediated immune escape of lung adenocarcinoma via STAT3/Jab1-PD-L1 signalling.
Zhu P; Jin Z; Kang G; Jia Y; Liu D; Zhang Q; Guo F; Jia Y; Jiao Y; Li J; Sun H; Ma X
Cell Commun Signal; 2022 Aug; 20(1):121. PubMed ID: 35971127
[TBL] [Abstract][Full Text] [Related]
7. N
Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
[TBL] [Abstract][Full Text] [Related]
8. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
9. ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis.
Liu H; Kuang X; Zhang Y; Ye Y; Li J; Liang L; Xie Z; Weng L; Guo J; Li H; Ma F; Chen X; Zhao S; Su J; Yang N; Fang F; Xie Y; Tao J; Zhang J; Chen M; Peng C; Sun L; Zhang X; Liu J; Han L; Xu X; Hung MC; Chen X
Cancer Cell; 2020 Mar; 37(3):324-339.e8. PubMed ID: 32183950
[TBL] [Abstract][Full Text] [Related]
10. NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer.
Qin G; Wang X; Ye S; Li Y; Chen M; Wang S; Qin T; Zhang C; Li Y; Long Q; Hu H; Shi D; Li J; Zhang K; Zhai Q; Tang Y; Kang T; Lan P; Xie F; Lu J; Deng W
Nat Commun; 2020 Apr; 11(1):1669. PubMed ID: 32245950
[TBL] [Abstract][Full Text] [Related]
11. FGFR1 promotes tumor immune evasion via YAP-mediated PD-L1 expression upregulation in lung squamous cell carcinoma.
Lu M; Wang K; Ji W; Yu Y; Li Z; Xia W; Lu S
Cell Immunol; 2022 Sep; 379():104577. PubMed ID: 35870429
[TBL] [Abstract][Full Text] [Related]
12. Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8
Fang W; Zhou T; Shi H; Yao M; Zhang D; Qian H; Zeng Q; Wang Y; Jin F; Chai C; Chen T
J Exp Clin Cancer Res; 2021 Jan; 40(1):4. PubMed ID: 33390170
[TBL] [Abstract][Full Text] [Related]
13. Mechanistic Insights of Anti-Immune Evasion by Nobiletin through Regulating miR-197/STAT3/PD-L1 Signaling in Non-Small Cell Lung Cancer (NSCLC) Cells.
Sp N; Kang DY; Lee JM; Jang KJ
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576006
[TBL] [Abstract][Full Text] [Related]
14. AIM2 fosters lung adenocarcinoma immune escape by modulating PD-L1 expression in tumor-associated macrophages via JAK/STAT3.
Ye H; Yu W; Li Y; Bao X; Ni Y; Chen X; Sun Y; Chen A; Zhou W; Li J
Hum Vaccin Immunother; 2023 Dec; 19(3):2269790. PubMed ID: 37877820
[TBL] [Abstract][Full Text] [Related]
15. eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma.
Chen X; Wang K; Jiang S; Sun H; Che X; Zhang M; He J; Wen Y; Liao M; Li X; Zhou X; Song J; Ren X; Yi W; Yang J; Chen X; Yin M; Cheng Y
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35347072
[TBL] [Abstract][Full Text] [Related]
16. Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.
Liu J; Yang Y; Wang H; Wang B; Zhao K; Jiang W; Bai W; Liu J; Yin J
Breast Cancer Res Treat; 2018 Sep; 171(2):345-357. PubMed ID: 29845474
[TBL] [Abstract][Full Text] [Related]
17. Juxtacrine Signaling Inhibits Antitumor Immunity by Upregulating PD-L1 Expression.
Yang WH; Cha JH; Xia W; Lee HH; Chan LC; Wang YN; Hsu JL; Ren G; Hung MC
Cancer Res; 2018 Jul; 78(14):3761-3768. PubMed ID: 29789418
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies.
Frydenlund N; Mahalingam M
Hum Pathol; 2017 Aug; 66():13-33. PubMed ID: 28694003
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-4458 Regulates PD-L1 Expression to Enhance Anti-tumor Immunity in NSCLC via Targeting STAT3.
Liu W; Liu R; Yuan R; Wang X
Mol Biotechnol; 2021 Dec; 63(12):1268-1279. PubMed ID: 34386930
[TBL] [Abstract][Full Text] [Related]
20. PD-L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer.
Ji X; Sui L; Song K; Lv T; Zhao H; Yao Q
Cancer Med; 2021 Jul; 10(14):4743-4751. PubMed ID: 34076351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
